Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 96Rectal Neoplasms 45Colorectal Neoplasms 45Carcinoma, Non-Small-Cell Lung 31Esophageal Neoplasms 28Esophageal Squamous Cell Carcinoma 24Stomach Neoplasms 22Lung Neoplasms 20Pancreatic Neoplasms 19Squamous Cell Carcinoma of Head and Neck 18Colonic Neoplasms 18Sarcoma 16Neoplasms 16Adenocarcinoma Of Esophagus 15Ovarian Neoplasms 14Neoplasm Metastasis 14Head and Neck Neoplasms 14Carcinoma, Hepatocellular 14Prostatic Neoplasms 13Urinary Bladder Neoplasms 12Uterine Cervical Neoplasms 10Inflammatory Breast Neoplasms 9Fallopian Tube Neoplasms 9Osteosarcoma 8Central Nervous System Neoplasms 8Carcinoma, Intraductal, Noninfiltrating 8Kidney Neoplasms 7Carcinoma, Ovarian Epithelial 7Recurrence 6Multiple Myeloma 6

Interventions

folfirinox 1Taxes 1Oxaliplatin 1Neoadjuvant Therapy 1Leucovorin 1Irinotecan 1Gemcitabine 1FAPI-46 1Endosonography 1Blood Specimen Collection 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Ductal Adenocarcinoma (PDAC) × Neoadjuvant Therapy × Clear all
NCT04990609 2025-05-21

EUS-RFA PANCARDINAL-1 Trial

The University of Texas Health Science Center, Houston

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma (PDAC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡